Product Description: MEDI-1814 is a fully human IgG1 antibody that targets the C terminus of Aβ42. MEDI-1814 binds to and sweeps away the circulated Aβ peptides, hence, restricting them from aggregating into toxic oligomers. MEDI-1814 can be used for the study of Alzheimer's diseases. The isotype control for MEDI-1814 can refer to Human IgG1 kappa, Isotype Control (HY-P99001)[1].
Applications: Neuroscience-Neurodegeneration
Formula: N/A
References: [1]Liu J, et al. Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer's Disease Immunotherapy. Drugs Aging. 2016 Oct;33(10):685-697.
Molecular Weight: N/A
Research Area: Neurological Disease
Target: Amyloid-β